Campus Guglielmo, Cocco Fabio, Carta Giovanna, Cagetti Maria Grazia, Simark-Mattson Charlotte, Strohmenger Laura, Lingström Peter
Department of Surgery, Microsurgery and Medical Sciences, Dental School, University of Sassari, Viale San Pietro 43/C, I-07100, Sassari, Italy,
Clin Oral Investig. 2014;18(2):555-61. doi: 10.1007/s00784-013-0980-9. Epub 2013 May 5.
A double-blind, randomised, placebo-controlled clinical trial was performed to validate the hypothesis that the use of lozenges containing Lactobacillus brevis CD2 (Inersan®, CD Investments srl) may reduce plaque pH, salivary mutans streptococci (ms) and bleeding on probing, during a 6-week period, in a sample of high caries risk schoolchildren.
A total of 191 children (aged 6-8 years), presenting two to three carious lesions and a salivary ms concentration of ≥10(5) CFU/ml, were enrolled and divided into two groups, an L. brevis CD2 lozenge group and a no L. brevis lozenge group, and examined at baseline (t0), after 3 weeks (t1), after 6 weeks of lozenge use (t2) and 2 weeks after the cessation of lozenge use (t3). Plaque pH was assessed using the microtouch technique following a sucrose challenge. The area under the curve (AUC5.7 and AUC6.2) was recorded. Salivary ms were counted, and bleeding on probing was assessed.
At t0, the plaque-pH and ms concentration values were similar in both groups. Mean areas (AUC5.7 and AUC6.2) were significantly greater in the control group at t1, t2 and t3. L. brevis CD2 lozenges significantly reduced salivary ms concentrations and bleeding. The subjects from the test group showed a statistically significant decrease (p = 0.01) in salivary ms concentration. At t2, a statistically significantly lower bleeding value was recorded in the test group compared with the control group (p = 0.02).
Six weeks' use of lozenges containing L. brevis CD2 had a beneficial effect on some important variables related to oral health, including a reduction in plaque acidogenicity, salivary ms and bleeding on probing. (Trial Registration Number NCT01601145 08/21/2012).
开展一项双盲、随机、安慰剂对照临床试验，以验证以下假设：对于高龋风险学龄儿童样本，在为期6周的时间里，使用含有短双歧杆菌CD2（Inersan®，CD Investments srl）的含片可降低菌斑pH值、唾液变形链球菌（ms）数量以及探诊出血情况。
共纳入191名6至8岁儿童，这些儿童有两至三处龋损且唾液ms浓度≥10⁵CFU/ml，将其分为两组，即短双歧杆菌CD2含片组和不含短双歧杆菌含片组，并在基线期（t0）、3周后（t1）、使用含片6周后（t2）以及停止使用含片2周后（t3）进行检查。在蔗糖激发试验后，采用微触技术评估菌斑pH值。记录曲线下面积（AUC5.7和AUC6.2）。对唾液ms进行计数，并评估探诊出血情况。
在t0时，两组的菌斑pH值和ms浓度值相似。在t1、t2和t3时，对照组的平均面积（AUC5.7和AUC6.2）显著更大。短双歧杆菌CD2含片显著降低了唾液ms浓度和出血情况。试验组受试者的唾液ms浓度有统计学意义的显著降低（p = 0.01）。在t2时，试验组的出血值与对照组相比有统计学意义的显著降低（p = 0.02）。
使用含有短双歧杆菌CD2的含片6周对一些与口腔健康相关的重要变量有有益影响，包括降低菌斑产酸性、唾液ms数量以及探诊出血情况。（试验注册号NCT01601145 2012年8月21日）
